恶性间皮瘤的靶向与免疫治疗

doi:10.16352/j.issn.1001-6325.2024.10.1342

摘要/Abstract

摘要： 恶性间皮瘤(malignant mesothelioma,MMe)是一种来源于间皮组织的恶性肿瘤,多发生在胸膜、心包膜和腹膜等处,由于难以治愈的特点,对其治疗的研究一直备受关注。传统的治疗手段包括手术、化疗和放疗,但因疗效有限,患者生存率仍然较低。因此,寻找新的治疗方法对于改善间皮瘤患者的预后至关重要。靶向治疗和免疫治疗作为新兴的癌症治疗手段,通过针对肿瘤细胞或免疫细胞的特定靶点来抑制肿瘤的生长和转移,为间皮瘤的治疗带来了新的希望。本文围绕间皮瘤的靶向治疗与免疫治疗新进展进行综述。

关键词: 间皮瘤, 靶向治疗, 免疫治疗, 溶瘤病毒, CAR-T

Abstract: Malignant mesothelioma (MMe) is a malignant tumor originating from mesothelial tissues, occurring mostly in locations like pleura, pericardium and peritoneum. The extensive research on its treatment has been carried on as tackling to the challenge of poor prognosis of the disease. Conventional treatment modalities including surgery, chemotherapy and radiotherapy all exhibit limited efficacy, resulting in persistently low survival rates. Hence, exploring novel therapeutic approaches is paramount for improving the prognosis of mesothelioma patients. Targeted therapy and immunotherapy, as emerging cancer treatment modalities, exert their effects by targeting specific molecular markers on tumor cells or immune cells, thus inhibiting tumor growth and metastasis, thereby offering new hope for mesothelioma treatment. This article provides a comprehensive review of recent research progress in targeted therapy and immunotherapy for mesothelioma.

Key words: mesothelioma, targeted therapy, immunotherapy, oncolytic virus, CAR-T

中图分类号:

杨俊豪, 赵林. 恶性间皮瘤的靶向与免疫治疗[J]. 基础医学与临床, 2024, 44(10): 1342-1349.

参考文献

[1]Milano MT, Zhang H. Malignant pleural mesothelioma: a population-based study of survival[J]. J Thorac Oncol, 2010, 5: 1841-1848. doi: 10.1097/JTO.0b013e3181f1cf2b.
[2]Carbone M, Kanodia S, Chao A, et al. Consensus report of the 2015 Weinman International Conference on mesothelioma[J]. J Thorac Oncol, 2016, 11: 1246-1262. doi: 10.1016/j.jtho.2016.04.028.
[3]Carbone M, Adusumilli PS, Alexander HR, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy[J]. CA Cancer J Clin, 2019,69:402-429. doi: 10.3322/caac.21572.
[4]Janes SM, Alrifai D, Fennell DA. Perspectives on the treatment of malignant pleural mesothelioma[J]. N Engl J Med, 2021,38:1207-1218. doi: 10.1056/NEJMra1912719.
[5]Tsao AS, Lindwasser OW, Adjei AA, et al. Current and future management of malignant mesothelioma: a consensus report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation[J]. J Thorac Oncol, 2018,13:1655-1667. doi: 10.1016/j.jtho.2018.08.2036.
[6]Marech I, Leporini C, Ammendola M, et al. Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment[J]. Cancer Lett, 2016,380:216-226. doi: 10.1016/j.canlet.2015.07.028.
[7]Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors[J]. Nat Med, 2003,9:669-676. doi: 10.1038/nm0603-669.
[8]Bonifazi M, Rossi M, Moja L, et al. Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety[J]. Oncologist, 2012,17:117-124. doi: 10.1634/theoncologist.2011-0184.
[9]Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2016,387:1405-1414. doi: 10.1016/S0140-6736(15)01238-6.
[10]Tsao AS, Moon J, Wistuba Ⅱ, et al. Phase I Trial of cediranib in combination with cisplatin and pemetrexed in chemonaive patients with unresectable malignant pleural mesothelioma (SWOG S0905)[J]. J Thorac Oncol, 2017,12:1299-1308. doi: 10.1016/j.jtho.2017.05.021.
[11]Cinausero M, Rihawi K, Cortiula F, et al. Emerging therapies in malignant pleural mesothelioma[J]. Crit Rev Oncol Hematol, 2019,144:102815. doi: 10.1016/j.critrevonc.2019.102815.
[12]Bueno R, Stawiski EW, Goldstein LD, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations[J]. Nat Genet, 2016,48:407-416. doi: 10.1038/ng.3520.
[13]Aliagas E, Alay A, Martínez-Iniesta M, et al. Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma[J]. Br J Cancer, 2021,125:1365-1376. doi: 10.1038/s41416-021-01547-y.
[14]Panou V, Gadiraju M, Wolin A, et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma[J]. J Clin Oncol, 2018,36:2863-2871. doi: 10.1200/JCO.2018.78.5204.
[15]Dacic S, Kothmaier H, Land S, et al. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas[J]. Virchows Arch, 2008,453:627-635. doi: 10.1007/s00428-008-0689-3.
[16]Paternot S, Raspé E, Meiller C, et al. Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition[J]. Mol Oncol, 2024,18:866-894. doi: 10.1002/1878-0261.13351.
[17]Borea F, Franczak MA, Garcia M, et al. Target therapy in malignant pleural mesothelioma: hope or mirage?[J]. Int J Mol Sci, 2023,24:9165. doi: 10.3390/ijms24119165.
[18]Mak G, Soria JC, Blagden SP, et al. A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours[J]. Br J Cancer, 2019,120:975-981. doi: 10.1038/s41416-019-0452-3.
[19]Soria JC, Gan HK, Blagden SP, et al. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors[J]. Ann Oncol, 2016,27:2268-2274. doi: 10.1093/annonc/mdw427.
[20]Fennell DA, Baas P, Taylor P, et al. Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND-a double-blind, randomized, phase Ⅱ Study[J]. J Clin Oncol, 2019,37:790-798. doi: 10.1200/JCO.2018.79.0543.
[21]Han A, Purwin TJ, Aplin AE. Roles of the BAP1 tumor suppressor in cell metabolism[J]. Cancer Res, 2021,81:2807-2814. doi: 10.1158/0008-5472.CAN-20-3430.
[22]Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase[J]. Nature, 2005,434:913-917. doi: 10.1038/nature03443.
[23]Fennell DA, King A, Mohammed S, et al. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial[J]. Lancet Respir Med, 2021,9:593-600. doi: 10.1016/S2213-2600(20)30390-8.
[24]Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting[J]. Annu Rev Immunol, 2004,22:329-360. doi:10.1146/annurev.immunol.22.012703.104803.
[25]Popat S, Curioni-Fontecedro A, Dafni U, et al. A multicentre randomised phase Ⅲ trial comparing pembroli-zumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial[J]. Ann Oncol, 2020,31:1734-1745. doi: 10.1016/j.annonc.2020.09.009.
[26]Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial[J]. Lancet Oncol, 2019,20:239-253. doi: 10.1016/S1470-2045(18)30765-4.
[27]Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet, 2021,397:375-386. doi: 10.1016/S0140-6736(20)32714-8.
[28]Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn[J]. Cancer Sci, 2016,107:1373-1379. doi: 10.1111/cas.13027.
[29]Mondal M, Guo J, He P, et al. Recent advances of oncolytic virus in cancer therapy[J]. Hum Vaccin Immunother,2020,16:2389-2402. doi: 10.1080/21645515.2020.1723363.
[30]Silberhumer GR, Brader P, Wong J, et al. Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesotheli-oma[J]. Mol Cancer Ther, 2010,9:2761-2769. doi: 10.1158/1535-7163.MCT-10-0090.
[31]Danson SJ, Conner J, Edwards JG, et al. Oncolytic herpesvirus therapy for mesothelioma-a phase Ⅰ/Ⅱa trial of intrapleural administration of HSV1716[J]. Lung Cancer, 2020,150:145-151. doi: 10.1016/j.lungcan.2020.10.007.
[32]Chen CY, Wang PY, Hutzen B, et al. Cooperation of oncolytic herpes virotherapy and PD-1 blockade in murine rhabdomyosarcoma models[J]. Sci Rep, 2017,7:2396. doi: 10.1038/s41598-017-02503-8.
[33]Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma[J]. J Clin Oncol, 2015,33:2780-2788. doi: 10.1200/JCO.2014.58.3377.
[34]Roy DG, Bell JC. Cell carriers for oncolytic viruses: current challenges and future directions[J]. Oncolytic Virother, 2013,2:47-56. doi: 10.2147/OV.S36623.
[35]Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies[J]. Blood Cancer J, 2021,11:69. doi: 10.1038/s41408-021-00459-7.
[36]Ghosn M, Cheema W, Zhu A, et al. Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase Ⅰ/Ⅱ clinical trial[J]. Lung Cancer, 2022,165:1-9. doi: 10.1016/j.lungcan.2022.01.003.
[37]Haas AR, Tanyi JL, O′Hara MH, et al. Phase Ⅰ study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers[J]. Mol Ther, 2019,27:1919-1929. doi: 10.1016/j.ymthe.2019.07.015.
[38]Adusumilli PS, Zauderer MG, Rivière I, et al. A phase Ⅰ trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab[J]. Cancer Discov, 2021,11:2748-2763. doi: 10.1158/2159-8290.CD-21-0407.
[39]Zeltsman M, Dozier J, McGee E, et al. CAR T-cell therapy for lung cancer and malignant pleural mesothelioma[J]. Transl Res, 2017,187:1-10. doi: 10.1016/j.trsl.2017.04.004.